The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- Sokoto govt, UNICEF, partners take polio vaccination to insecurity-hit communities
- Radiographers push for stronger patient protection
- Long queues dampen CNG’s cost benefits
- SSANU resumes work at Sokoto varsity, issues fresh 14-day strike ultimatum
- NNPC: Gas network available, not responsible for current power generation decline
- ANPMP strengthens Nigeria’s Ebola response
- NCF unveils Asiodu tree-planting legacy project
- Bauchi, Gombe boost environmental health monitoring
